<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711306</url>
  </required_header>
  <id_info>
    <org_study_id>201209019</org_study_id>
    <nct_id>NCT02711306</nct_id>
  </id_info>
  <brief_title>Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome</brief_title>
  <official_title>Office of Human Research, Taipei Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic syndrome (MS) is a complex disease with a cluster of risk factors and clinical
      features, which includes central or abdominal obesity, atherogenic dyslipidemia, impaired
      glucose regulation, hyperinsulinemia, high blood pressure, and concomitance of
      pro-inflammatory cytokine and insulin resistance. Glucomannan (GM) is a water-soluble dietary
      fiber derived from the root of Amorphophallus konjac that can improve blood sugar, blood fat
      concentration, and weight management, and has other health benefits.The purposes of this
      study are going to investigate the effects of KGM noodle (KGN) as stable food to MS and
      diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The KGN diet was composed of well-cooked noodle with 2 g of KGM in a dosage of 200 g/piece
      twice daily to substitute the daily carbohydrate for 4 weeks, with a 2-week washout period
      between alternative diets. All 33 subjects received two servings of either GMNs or PNs (400
      g) per day, which replaced the main carbohydrate in two daily meals for 4 weeks. After a
      2-week washout period, the subjects received the other type of noodle for 4 weeks. The body
      weight, BMI, waist circumference, fasting blood glucose and lipid profile, as well as serum
      vitamin A, E, Î²-carotene and high sensitivity C-reactive protein (hs-CPR) were measured by
      HPCL.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Weight</measure>
    <time_frame>4 weeks</time_frame>
    <description>Body weight by weighting scale (kilogram). Lower scores mean a better outcome in subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>4 weeks</time_frame>
    <description>Body waist by tape in centimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>HbA1c (glycated hemoglobin) analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Index</measure>
    <time_frame>4 weeks</time_frame>
    <description>LDL-C (low density lipoprotein cholesterol) analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>GMN Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PN Diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucomannan noodle</intervention_name>
    <description>The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.</description>
    <arm_group_label>GMN Diet</arm_group_label>
    <arm_group_label>PN Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo noodle</intervention_name>
    <description>In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.</description>
    <arm_group_label>GMN Diet</arm_group_label>
    <arm_group_label>PN Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Adults with metabolic syndrome

        Subjects were considered to have metabolic syndrome if subjects had 3 of the following 5
        characteristics:

          1. Abdominal obesity (waist circumference &gt;= 90 cm in men and &gt;= 80 cm in women)

          2. Impaired fasting glucose ( &gt;= 5.6 mmol/L)

          3. Hypertriglyceridemia ( &gt;= 1.7 mmol/L)

          4. Low HDL-C (&lt; 1.0 mmol/L in men and &lt; 1.3 mmol/L in women)

          5. Increased blood pressure (SBP &gt;= 130 mmHg and DBP &gt;= 85 mmHg).

        Exclusion Criteria:

          1. Liver and renal diseases

          2. Undergoing statin therapy

          3. Pregnancy women

          4. Taking antioxidant vitamins supplements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Han Lin, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Office of Human Research, Taipei Medical University</affiliation>
  </overall_official>
  <reference>
    <citation>Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008 Oct;88(4):1167-75. Review.</citation>
    <PMID>18842808</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>March 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <results_first_submitted>January 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2019</results_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>(1-6)-alpha-glucomannan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>First GMN Then PN</title>
          <description>&quot;First Intervention (4 weeks, GMN)&quot;, &quot;Washout (2 weeks)&quot; and &quot;Second Intervention (4 weeks, PN)&quot;</description>
        </group>
        <group group_id="P2">
          <title>First PN Then GMN</title>
          <description>&quot;First Intervention (4 weeks, PN)&quot;, &quot;Washout (2 weeks)&quot; and &quot;Second Intervention (4 weeks, GMN)&quot;</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>First GMN Then PN</title>
          <description>&quot;First Intervention (4 weeks, GMN)&quot;, &quot;Washout (2 weeks)&quot; and &quot;Second Intervention (4 weeks, PN)&quot;</description>
        </group>
        <group group_id="B2">
          <title>First PN Then GMN</title>
          <description>&quot;First Intervention (4 weeks, PN)&quot;, &quot;Washout (2 weeks)&quot; and &quot;Second Intervention (4 weeks, GMN)&quot;</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.75" spread="4.96"/>
                    <measurement group_id="B2" value="49.82" spread="12.59"/>
                    <measurement group_id="B3" value="50.79" spread="10.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Weight</title>
        <description>Body weight by weighting scale (kilogram). Lower scores mean a better outcome in subjects.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GMN Diet</title>
            <description>In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.</description>
          </group>
          <group group_id="O2">
            <title>PN Diet</title>
            <description>In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight</title>
          <description>Body weight by weighting scale (kilogram). Lower scores mean a better outcome in subjects.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="10.86"/>
                    <measurement group_id="O2" value="74.97" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.41" spread="10.49"/>
                    <measurement group_id="O2" value="74.39" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>Body waist by tape in centimeter</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GMN Diet</title>
            <description>In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.</description>
          </group>
          <group group_id="O2">
            <title>PN Diet</title>
            <description>In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>Body waist by tape in centimeter</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.03" spread="6.69"/>
                    <measurement group_id="O2" value="91.14" spread="7.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.17" spread="6.8"/>
                    <measurement group_id="O2" value="90.15" spread="7.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Index</title>
        <description>HbA1c (glycated hemoglobin) analysis</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GMN Diet</title>
            <description>In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.</description>
          </group>
          <group group_id="O2">
            <title>PN Diet</title>
            <description>In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Index</title>
          <description>HbA1c (glycated hemoglobin) analysis</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" spread="1.65"/>
                    <measurement group_id="O2" value="7.21" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="1.54"/>
                    <measurement group_id="O2" value="7.12" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Index</title>
        <description>LDL-C (low density lipoprotein cholesterol) analysis</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GMN Diet</title>
            <description>In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.</description>
          </group>
          <group group_id="O2">
            <title>PN Diet</title>
            <description>In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Index</title>
          <description>LDL-C (low density lipoprotein cholesterol) analysis</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.86" spread="32.54"/>
                    <measurement group_id="O2" value="135.39" spread="28.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.24" spread="33.99"/>
                    <measurement group_id="O2" value="130.53" spread="33.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data were collected from the participants during intervention and assessed after 6 months.</time_frame>
      <desc>Adverse events were reported in real time, as they occurred (if any) by a physician who saw the subjects each day. As this was a dietary analysis/no pharmacological intervention, no adverse events were expected.</desc>
      <group_list>
        <group group_id="E1">
          <title>GMN Diet</title>
          <description>The 100 g GMN noodle contains 1 g of konjac glucomannan powder. Participants approximately consumed 2 g GMN per day in 200 g of noodle. The intervention period was 4 weeks long. Meanwhile, the participants remained their usual eating habits except consuming any probiotics or prebiotics.</description>
        </group>
        <group group_id="E2">
          <title>PN Diet</title>
          <description>Isocaloric noodle with no konjac glucomannan powder in placebo comparator. The PN-participants daily consumed placebo noodle without any added GMN (approximately 200 g noodle per day). The intervention period was 4 weeks long. Meanwhile, the participants will remain their usual eating habits except consuming any probiotics or prebiotics.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sing-Chung Li</name_or_title>
      <organization>Taipei Medical University</organization>
      <phone>886-2-27361661 ext 6560</phone>
      <email>sinchung@tmu.edu.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

